<DOC>
	<DOCNO>NCT01534585</DOCNO>
	<brief_summary>Nasopharyngeal carcinoma ( NPC ) prevalent disease southeast China . Radiation therapy without chemotherapy standard therapy nasopharyngeal cancer . Cytotoxic chemotherapy play important role curative treatment advance NPC . However , concurrent chemoradiotherapy increase significantly local systemic toxic effect , may preclude many patient proceed combined therapy . The epidermal growth factor receptor ( EGFR ) gene amplify 40 % EGFR protein overexpressed 80 % NPC . EGFR overexpression also associate short survival follow chemoradiotherapy locoregionally advanced NPC . And basic research prove EGFR tyrosine kinase inhibitor ( TKIs ) could increase radiosensitivity reduce epithelial-mesenchymal transition ( EMT ) NPC cell line . Moreover , distant metastasis major cause treatment failure NPC . Icotinib hydrochloride novel oral EGFR TKIs low mammalian toxicity ( make China ) . But base toxic effect Icotinib , may increase toxic effect skin mucosa combination therapy Icotinib Intensity-modulated Radiotherapy ( IMRT ) . The prospective study assess tolerability efficacy Icotinib combine IMRT patient NPC . This regimen great interest potential alleviate adverse effect , improve patient compliance well therapeutic ratio .</brief_summary>
	<brief_title>Safety Efficacy Study Icotinib With Intensity-modulated Radiotherapy Nasopharyngeal Carcinoma</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Nasopharyngeal Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Mitogens</mesh_term>
	<criteria>1 . Patients histological proof squamous carcinoma nasopharynx . 2 . Patients must ECOG Performance Status 01 . 3 . Patients adequate bone marrow function define absolute peripheral granulocyte count ( AGC ) &gt; /= 1500 cells/mm3 , platelet count &gt; /= 100,000 cells/mm3 ; adequate hepatic function bilirubin &lt; /= 1.5mg/dl , AST ALT &lt; /= 2x upper limit normal ; serum creatinine &lt; /= 1.5mg/dl , creatinine clearance &gt; /= 50 ml/min INR 0.8 1.2 . 4 . Patients must sign study specific informed consent form prior study entry . 1 . Evidence metastases clinical radiographic examination . 2 . History malignancy nonmelanoma skin cancer . 3 . Prior chemotherapy anticancer biologic therapy type cancer , prior radiotherapy head neck region except radioactive iodine therapy . 4 . Patients uncontrolled intercurrent disease . 5 . Patients currently active malignancy . 6 . Pregnant lactate woman Female patient childbearing potential unwilling practice adequate contraception study treatment two month last administration study drug .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>February 2012</verification_date>
	<keyword>nasopharyngeal carcinoma ( NPC )</keyword>
	<keyword>Icotinib</keyword>
	<keyword>Intensity Modulation Radiation Therapy ( IMRT )</keyword>
</DOC>